The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan - PubMed (original) (raw)
The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
K Hiramatsu. Am J Med. 1998.
Abstract
Within the past year, infections caused by methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to vancomycin (MIC=8 microg/mL) have been reported in both Japan and the United States. The emergence of these strains poses a potentially serious threat to public health. After 2 such strains (Mu3 and Mu50) were identified at Juntendo Hospital in 1996, a screening program to identify MRSA strains with reduced susceptibility to vancomycin was initiated. Of 970 MRSA strains tested at 195 nonuniversity hospitals throughout Japan, 13 (1.3%) were found to have subpopulations with reduced vancomycin susceptibility (heterogeneous vancomycin resistance). Among 129 MRSA strains identified at 7 university hospitals, 12 (9.3%) demonstrated heterogeneity for vancomycin resistance; 1 of these strains had a vancomycin MIC of 7 microg/mL. Although resistance in these strains is not the result of the transfer of enterococcal vancomycin resistance genes (vanA or vanB), the clonal dissemination of MRSA strains with vancomycin-resistant subpopulations is obviously undesirable. Intensified testing of MRSA strains for resistance to vancomycin and appropriate measures for the prevention of the spread of such strains are recommended.
Similar articles
- Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.
Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. Hiramatsu K, et al. Lancet. 1997 Dec 6;350(9092):1670-3. doi: 10.1016/S0140-6736(97)07324-8. Lancet. 1997. PMID: 9400512 - Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.
Ike Y, Arakawa Y, Ma X, Tatewaki K, Nagasawa M, Tomita H, Tanimoto K, Fujimoto S. Ike Y, et al. J Clin Microbiol. 2001 Dec;39(12):4445-51. doi: 10.1128/JCM.39.12.4445-4451.2001. J Clin Microbiol. 2001. PMID: 11724859 Free PMC article. - First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.
Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, Dhiraputra C, Susaemgrat W, Ito T, Hiramatsu K. Trakulsomboon S, et al. J Clin Microbiol. 2001 Feb;39(2):591-5. doi: 10.1128/JCM.39.2.591-595.2001. J Clin Microbiol. 2001. PMID: 11158112 Free PMC article. - Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC. Appelbaum PC. Int J Antimicrob Agents. 2007 Nov;30(5):398-408. doi: 10.1016/j.ijantimicag.2007.07.011. Epub 2007 Sep 20. Int J Antimicrob Agents. 2007. PMID: 17888634 Review. - Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G, Moellering RC Jr. Sakoulas G, et al. Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S360-7. doi: 10.1086/533592. Clin Infect Dis. 2008. PMID: 18462091 Review.
Cited by
- Triple threat: how diabetes results in worsened bacterial infections.
Darwitz BP, Genito CJ, Thurlow LR. Darwitz BP, et al. Infect Immun. 2024 Sep 10;92(9):e0050923. doi: 10.1128/iai.00509-23. Epub 2024 Mar 25. Infect Immun. 2024. PMID: 38526063 Free PMC article. Review. - The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity.
Singh A, Kaur K, Mohana P, Singh K, Sharma A, Prajapati J, Goswami D, Khosla N, Kaur U, Kaur R, Kaur R, Rana A, Kour S, Ohri P, Arora S, Chadha R, Singh Bedi PM. Singh A, et al. RSC Med Chem. 2023 Nov 20;15(1):234-253. doi: 10.1039/d3md00580a. eCollection 2024 Jan 25. RSC Med Chem. 2023. PMID: 38283229 - Diclofenac and Meloxicam Exhibited Anti-Virulence Activities Targeting Staphyloxanthin Production in Methicillin-Resistant Staphylococcus aureus.
Elmesseri RA, Saleh SE, Ghobish SA, Majrashi TA, Elsherif HM, Aboshanab KM. Elmesseri RA, et al. Antibiotics (Basel). 2023 Jan 31;12(2):277. doi: 10.3390/antibiotics12020277. Antibiotics (Basel). 2023. PMID: 36830188 Free PMC article. - Two Novel Semisynthetic Lipoglycopeptides Active against Staphylococcus aureus Biofilms and Cells in Late Stationary Growth Phase.
Vimberg V, Zieglerova L, Mazumdar A, Szűcs Z, Borbás A, Herczegh P, Novotna GB. Vimberg V, et al. Pharmaceuticals (Basel). 2021 Nov 19;14(11):1182. doi: 10.3390/ph14111182. Pharmaceuticals (Basel). 2021. PMID: 34832964 Free PMC article. - Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA).
Thitiananpakorn K, Aiba Y, Tan XE, Watanabe S, Kiga K, Sato'o Y, Boonsiri T, Li FY, Sasahara T, Taki Y, Azam AH, Zhang Y, Cui L. Thitiananpakorn K, et al. Sci Rep. 2020 Sep 30;10(1):16107. doi: 10.1038/s41598-020-73108-x. Sci Rep. 2020. PMID: 32999359 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous